Selected Clients:

As developing Asian markets increasingly clamor for advanced medical care, foreign multinationals are seeing accelerating sales growth in Asian health sectors. As opportunities abound in the CRO, pharmaceutical, and medical devices sector, international pharma and medical device manufacturers will continue to invest in overseas expansion in Asia.

BDA has worked for major healthcare companies from North America, Europe and Asia on a wide range of strategic projects and corporate finance transactions, such as:

  • Advised on establishing animal vaccine JV in China with Jilin Guoyuan Animal Health for Pfizer
  • Advised on divesting Swine MH vaccine business in China to Harbin Pharmaceutical Group for Pfizer
  • Advised on the acquisition of the Applied Biosystems distribution business of LabIndia Instruments by Life Technologies
  • Advised on acquisition of life sciences target in China for Millipore
  • Advised on a health products acquisition in Japan for Kimberly-Clark
  • Identification of targets in the Chinese pharmaceutical /biopharmaceutical sector for Rohm and Haas
  • Search and advisor on proposed acquisition of Chinese pharmaceutical company for Solvay
  • Adviser on investment in the Japanese HRT sector for Teikoku Hormone

Browse BDA's Asian Health Newsletters

 
New York   |   London   |   Shanghai  |   Hong Kong   |    Mumbai   |   Tokyo |   Seoul   |   Bahrain   
Copyright 2011 |  Business Development Asia. Maintained by Pro Data.